Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mirum Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mirum Pharmaceuticals's regulatory disclosures and financial reporting.
Mirum Pharmaceuticals, Inc. received an amended Schedule 13G showing that Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 2,093,582 shares of common stock, representing 4.1% of the class. Eventide has sole voting and dispositive power over these shares, while Kuruvilla and John report shared voting and dispositive power over the same amount. The group states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Mirum. The filers also expressly disclaim beneficial ownership of the securities covered by the statement and make a joint filing agreement under Rule 13d-1(k)(1).
Mirum Pharmaceuticals President and COO Peter Radovich reported a sale of company common stock in a Form 4 filing. On February 2, 2026, he sold 2,631 shares of common stock at an average price of $103.3035 per share. According to the footnote, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. After this transaction, he beneficially owned 20,655 shares of Mirum Pharmaceuticals common stock directly.
Mirum Pharmaceuticals, Inc.’s chief executive officer and director Christopher Peetz reported a sale of 9,108 shares of common stock on February 2, 2026 at a price of $103.3035 per share. The filing states these shares were sold to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Peetz beneficially owned 160,294 Mirum common shares directly and 187,500 shares indirectly through The Peetz Family Trust. This reflects a routine, tax-related insider transaction rather than an open-market discretionary sale.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity compensation activity. On January 31, 2026, 1,771 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0.
On February 2, 2026, Howe sold 968 shares of common stock at a price of $103.3035 per share to cover tax withholding obligations related to the vesting. After these transactions, Howe directly owned 4,503 shares of Mirum Pharmaceuticals common stock.
Mirum Pharmaceuticals insider Jolanda Howe has filed to sell 968 shares of common stock. The planned sale through Morgan Stanley Smith Barney on NASDAQ has an aggregate market value of $100,478.40, with 51,393,574 common shares shown as outstanding.
The 968 shares to be sold were acquired on January 31, 2026 as restricted stock units vesting under a registered plan, received as compensation for services to the company. In the prior three months, Howe sold 926 shares on January 22, 2026 for $86,419.16 and 842 shares on January 26, 2026 for $80,993.67.
Mirum Pharmaceuticals insider Peter Radovich has filed a Form 144 indicating an intent to sell 2,631 shares of common stock through Morgan Stanley Smith Barney LLC on or about February 2, 2026 on NASDAQ, with an aggregate market value of $273,097.80.
The 2,631 shares were acquired on January 31, 2026 as restricted stock units vesting under a registered plan, as compensation for services to the issuer. In the prior three months, Radovich sold 2,382 shares for $222,300.69 on January 22, 2026 and 3,143 shares for $302,331.46 on January 26, 2026.
Mirum Pharmaceuticals shareholder Christopher Peetz has filed a Rule 144 notice to sell 9,108 shares of common stock. The planned sale, through Morgan Stanley Smith Barney on the NASDAQ around 02/02/2026, has an aggregate market value of $945,410.40, with 51,393,574 shares outstanding.
The shares to be sold were acquired on 01/31/2026 when restricted stock units vested under a registered plan as compensation for services to Mirum. The filing also notes earlier January 2026 sales of 7,098 and 6,831 shares of common stock for gross proceeds of $662,422.46 and $657,087.57, respectively.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported new equity awards in the company. On January 28, 2026, she received stock options for 7,680 shares of common stock with an exercise price of $100.85 per share, vesting over four years starting one year after that date.
She was also granted 4,970 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 9,000 performance restricted stock units previously granted on January 23, 2024 were confirmed to have met their performance criteria, and will vest two-thirds on March 15, 2026 and one-third on March 15, 2027.
Mirum Pharmaceuticals reported new equity awards for its Chief Medical Officer, Joanne Quan, dated January 28, 2026. She received a stock option for 18,140 shares at an exercise price of $100.85 per share. One quarter of this option vests one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.
Quan was also granted 11,760 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 20,000 performance restricted stock units (PSUs) granted on January 23, 2024, had their performance criteria determined to be met on January 28, 2026. Two thirds of the PSU shares will vest on March 15, 2026 and the remaining one third on March 15, 2027.
Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt received new equity awards on January 28, 2026. He was granted stock options for 18,140 shares of common stock at an exercise price of $100.85 per share, plus 11,760 restricted stock units and 20,000 performance-based restricted stock units.
The stock options vest over four years, with one-quarter vesting one year after January 28, 2026 and the remainder in 36 equal monthly installments. The restricted stock units vest in three equal annual installments from the same date. The performance units vest two-thirds on March 15, 2026 and one-third on March 15, 2027 after performance criteria were met.